Company intelligence / Profile preview

Ever-More Biopharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Ever-More Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative oncology therapeutics. The company specializes in developing next-generation small molecules and biologics, including antibody-drug conjugates (ADCs) and targeted therapies for solid tumors. Their pipeline features candidates targeting well-validated pathways such as EGFR and HER2, with a focus on overcoming resistance in lung and breast cancers. Ever-More aims to address significant unmet medical needs in the global oncology market through internal R&D and strategic collaborations.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Ever-More Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ever-More Biopharmaceutical.

Explore the full profile